Development of Recombinant Protein Overproducer Cell Lines with Lentiviral Expression Vectors
6 Dec 2018Custom overproducer cell line services are offered using the developed protocols, for the development of a wide range of cell lines overproducing recombinant proteins. Using Cellecta’s lentiviral system, a construct containing the gene of interest can be packaged into VSV-g pseudotyped viral particles and delivered into a wide range of mammalian cells. With an average development time of 6 weeks, these cell lines dramatically improve the efficiency of process development and can be used for preparative and industrial-scale production of proteins.
Related Products
Request Quote for All Products
Ready-to-Use Lentiviral Packaging Plasmid Mix
CellectaCellecta’s Ready-to-Use Lentiviral Packaging Plasmid Mix allows the production of pseudoviral particles when mixed with second- or third-generation lentiviral vectors. The Packaging Plasmid Mix is a mixture of the human immunodeficiency virus (HIV) lentiviral packaging plasmid psPAX2 and the pMD2.G plasmid containing VSV-G. These plasmids provide all the necessary structural, regulatory, and replication proteins required to produce pseudotyped packaged lentiviral expression constructs when co-transfected with an HIV-based lentiviral expression construct (e.g. Cellecta pRSI shRNA expression constructs) into a producer 293T cell line (e.g. ATCC, Cat.# CRL-11268™). Pseudotyped lentiviral particles with VSV-G envelope protein can infect a variety of mammalian or non-mammalian, dividing or non-dividing cells. The kit contains 250 µg of lentiviral packaging plasmid mix that will be sufficient for 25 transfections in 10-cm culture plates. Cellecta’s packaging mix contains tested anion-exchange purified packaging plasmids pre-mixed at the proper ratio for optimal production of packaged VSV-g pseudotyped lentiviral particles. This reagent is used in conjunction with HEK 293T cells. The Ready-to-Use Lentiviral Packaging Plasmid Mix is compatible with most commercially-available second- and third-generation lentiviral vectors.